- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04962594
Safety and Efficacy of Infant Formulas Supplemented With Pre- and Probiotic(s) (CLARA)
Safety and Efficacy of Starter Infant Formula, Follow-up Formula and Growing-up Milk Supplemented With Pre- and Probiotic(s): a Double-blind, Randomized, Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, controlled, multicenter, double-blind study of healthy term infants, consisting of two randomized formula-fed arms (control and experimental formulas) and a non-randomized breast-fed reference group.
The population under investigation are healthy infants aged ≤14 days at enrollment. The planned sample size for formula-fed infants is 236 (118 per study group). A non-randomized breastfed reference group of 90 healthy, term, exclusively breastfed infants up to 4 months will also be enrolled.
Study formulas are administrated orally, ad libitum, from enrollment until 15 months of age.
The primary objective of the trial is to demonstrate the safety of a starter infant formula supplemented with pre- and probiotic(s) by comparing the growth (weight gain, g/day) of infants randomized to the experimental formula versus the control formula from enrolment to 4 months of age.
In addition fecal microbiome, fecal metabolic profile, fecal markers of immune and gut health, blood markers of immune health (in a subset of 60 infants/group), GI tolerance, bone index (subset of 40 infants/group), other anthropometric measurements, dietary pattern and infant illness and infection outcomes will be assessed/measured.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Brugge, Belgium, 8000
- AZ Sint-Jan Brugge-Oostende AV
-
Brussel, Belgium, 1090
- Universitair Ziekenhuis Brussel
-
Hasselt, Belgium, 3500
- Kinderartsen Huis
-
Liège, Belgium, 4000
- CHC-Groupe santé, Clinique MontLégia
-
Liège, Belgium, 4000
- CHU de Liège - CHR de la Citadelle
-
-
-
-
-
Amiens, France, 80054
- CHU Amiens-Picardie
-
Bron, France, 69677
- Hopital Femme Mere Enfant
-
Lyon, France, 69004
- Hôpital de la Croix Rousse
-
Nantes, France
- CHU de Nantes
-
Rouen, France, 76031
- CHU Charles Nicolle
-
Tours, France, 37044
- Hôpital Bretonneau, CHRU de Tours
-
-
-
-
-
Rostock, Germany, 18059
- Klinikum Südstadt Rostock
-
Spandau, Germany, 13589
- Evangelisches Waldkrankenhaus Spandau
-
-
-
-
-
Castellón De La Plana, Spain
- Hospital Vithas Castellón
-
Córdoba, Spain, 14004
- Reina Sofia University Hospital
-
Sevilla, Spain, 41014
- Instituto Hispalense de Pediatría, Unidad de Investigación
-
Valencia, Spain
- Hospital Vithas Valencia
-
Valencia, Spain
- Quironsalud Valencia Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Evidence of personally signed and dated informed consent document indicating that the infant's parent(s)/ legally accepted representatives LAR have been informed of all pertinent aspects of the study.
- Infants whose parent(s)/LAR have reached the legal age of majority in the countries where the study is conducted.
- Infants whose parent(s)/LAR are willing and able to comply with scheduled visits, and the requirements of the study protocol.
- Infants whose parent(s)/LAR are able to be contacted directly by telephone throughout the study.
Infants must meet all of the following inclusion criteria to be eligible for enrollment into the study:
- Healthy term infant (≥37 weeks of gestation)
- At enrollment visit, post-natal age ≤14 days/0.5 months
- Birth weight ≥ 2500g and ≤ 4500g.
- For formula-fed groups, infants must be exclusively consuming and tolerating a cow's milk infant formula at time of enrollment and their parent(s)/LAR must have independently elected, before enrollment, not to breastfeed.
- For the breastfed group, infants must have been exclusively consuming breast milk since birth, and their parent(s)/LAR must have made the decision to continue exclusively breastfeeding until at least 4 months of age.
Exclusion Criteria:
- Infants with conditions requiring infant feedings other than those specified in the protocol.
Infants who have a medical condition or history that could increase the risk associated with study participation or interfere with the interpretation of study results, including:
- Evidence of major congenital malformations (e.g., cleft palate, extremity malformation)
- Suspected or documented systemic or congenital infections (e.g., human immunodeficiency virus, cytomegalovirus, syphilis)
- Previous or ongoing severe medical or laboratory abnormality (acute or chronic) which, in the judgment of the investigator, would make the infant inappropriate for entry into the study. Of note, children who are normally healthy but at the time of enrollment suffering from acute illness in a minor condition which are common in childhood and do not require some of the exclusionary medication mentioned below can be enrolled.
- Infants who are presently receiving or have received prior to enrollment any of the following: medication(s) or supplement(s) which are known or suspected to affect the following: fat digestion, absorption, and/or metabolism (e.g., pancreatic enzymes); stool microbiota and characteristics (e.g., oral or systemic antibiotics, glycerin suppositories, bismuth-containing medications, docusate, Maltsupex, or lactulose); growth (e.g. insulin or growth hormone); gastric acid secretion.
- Currently participating or having participated in another clinical trial since birth.
- Subjects or subjects' parent(s) or legal representative who are not willing and not able to comply with scheduled visits and the requirements of the study protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental formulas (EF) group
Starter infant formula, follow-up infant formula and growing-up milk (partially hydrolyzed bovine whey protein) supplemented with pre- and probiotic(s)
|
First age formula administered orally ad libitum until 6 months of age, switch to second age formula until 12 months and finally to growing-up milk from 12 to 15 months
|
Active Comparator: Control formulas (CF) group
Starter infant formula, follow-up infant formula and growing-up milk (partially hydrolyzed bovine whey protein) not supplemented
|
First age formula administered orally ad libitum until 6 months of age, switch to second age formula until 12 months and finally to growing-up milk from 12 to 15 months
|
Active Comparator: Breastfed (BF) group
Breast milk
|
Exclusive breast feeding up to 4 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Weight
Time Frame: From baseline (≤14 days) to 4 months of age
|
Weight gain measured as mean daily weight gain in g/day
|
From baseline (≤14 days) to 4 months of age
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bifidobacteria abundance
Time Frame: At 90 days (3 months of age)
|
Bifidobacteria abundance
|
At 90 days (3 months of age)
|
Fecal microbiome
Time Frame: Stool sample collected at ≤14 days (baseline), 3, 6, 12 and 15 months of age
|
Overall fecal microbiota composition, diversity, different bacteria taxa and microbiota community types assessed using next generation sequencing (NGS) technology
|
Stool sample collected at ≤14 days (baseline), 3, 6, 12 and 15 months of age
|
Fecal metabolic profile: fecal pH
Time Frame: Stool sample collected at ≤14 days (baseline), 3, 6, 12 and 15 months of age
|
Fecal pH
|
Stool sample collected at ≤14 days (baseline), 3, 6, 12 and 15 months of age
|
Fecal metabolic profile: fecal organic acids
Time Frame: Stool sample collected at ≤14 days (baseline), 3, 6, 12 and 15 months of age
|
Fecal organic acids (such as, but not restricted to lactate, including indole-lactate, L- and D-lactate, propionate, butyrate, acetate, valerate, and total fecal organic acids)
|
Stool sample collected at ≤14 days (baseline), 3, 6, 12 and 15 months of age
|
Fecal markers of immune health and gut barrier
Time Frame: Stool sample collected at ≤14 days (baseline), 3, 6, 12 and 15 months of age
|
Fecal markers of immune health and gut barrier such as total secretory IgA (sIgA), lipocalin-2, calprotectin, and α-1-antitrypsin assessed by ELISA.
|
Stool sample collected at ≤14 days (baseline), 3, 6, 12 and 15 months of age
|
Fecal cytokine profile
Time Frame: Stool sample collected at ≤14 days (baseline), 3, 6, 12 and 15 months of age
|
Fecal cytokine profile (such as but not restricted to: IL-6, IL-8, IL-1b, IL-22, IFN-γ) using multiplex assays
|
Stool sample collected at ≤14 days (baseline), 3, 6, 12 and 15 months of age
|
Blood markers of immune health
Time Frame: At 4 months of age
|
Vaccine specific antibodies assessed by ELISA and Immuno-phenotyping in a subset of 120 infants (60/group)
|
At 4 months of age
|
GI-related behavior: stool frequency
Time Frame: Retrospective 1-day (at baseline) and prospective for 3 days prior to 1, 2, 3, 4, 6, 9, 12 and 15 months of age
|
Stool frequency recorded via the GI Symptom and Behavior Diary
|
Retrospective 1-day (at baseline) and prospective for 3 days prior to 1, 2, 3, 4, 6, 9, 12 and 15 months of age
|
GI-related behavior: stool consistency
Time Frame: Retrospective 1-day (at baseline) and prospective for 3 days prior to 1, 2, 3, 4, 6, 9, 12 and 15 months of age
|
Stool consistency recorded via the GI Symptom and Behavior Diary
|
Retrospective 1-day (at baseline) and prospective for 3 days prior to 1, 2, 3, 4, 6, 9, 12 and 15 months of age
|
GI-related behavior: incidence of spitting
Time Frame: Retrospective 1-day (at baseline) and prospective for 3 days prior to 1, 2, 3, 4, 6, 9, 12 and 15 months of age
|
Incidence of spitting recorded via the GI Symptom and Behavior Diary
|
Retrospective 1-day (at baseline) and prospective for 3 days prior to 1, 2, 3, 4, 6, 9, 12 and 15 months of age
|
GI-related behavior: incidence of flatulence
Time Frame: Retrospective 1-day (at baseline) and prospective for 3 days prior to 1, 2, 3, 4, 6, 9, 12 and 15 months of age
|
Incidence of flatulence via the GI Symptom and Behavior Diary
|
Retrospective 1-day (at baseline) and prospective for 3 days prior to 1, 2, 3, 4, 6, 9, 12 and 15 months of age
|
GI-related behavior: crying time
Time Frame: Retrospective 1-day (at baseline) and prospective for 3 days prior to 1, 2, 3, 4, 6, 9, 12 and 15 months of age
|
Crying time via the GI Symptom and Behavior Diary
|
Retrospective 1-day (at baseline) and prospective for 3 days prior to 1, 2, 3, 4, 6, 9, 12 and 15 months of age
|
GI-related behavior: sleep time
Time Frame: Retrospective 1-day (at baseline) and prospective for 3 days prior to 1, 2, 3, 4, 6, 9, 12 and 15 months of age
|
Sleep time via the GI Symptom and Behavior Diary
|
Retrospective 1-day (at baseline) and prospective for 3 days prior to 1, 2, 3, 4, 6, 9, 12 and 15 months of age
|
GI-related behaviour: volume of formula consumed
Time Frame: Retrospective 1-day (at baseline) and prospective for 3 days prior to 1, 2, 3, 4, 6, 9, 12 and 15 months of age
|
Volume of formula consumed at each feeding or the number of breast milk feedings recorded via the GI Symptom and Behavior Diary
|
Retrospective 1-day (at baseline) and prospective for 3 days prior to 1, 2, 3, 4, 6, 9, 12 and 15 months of age
|
Infant Gastrointestinal Symptom Index
Time Frame: At baseline, 1, 2, 3, 4, 6, 9, 12 and 15 months of infant age
|
GI symptoms via the Infant Gastrointestinal Symptom Questionnaire (IGSQ-13)
|
At baseline, 1, 2, 3, 4, 6, 9, 12 and 15 months of infant age
|
Bone index
Time Frame: At baseline, 3, 6, 9, 12 and 15 months of infant age
|
Bone index measurement will be conducted using a non-invasive and radiation-free ultra-sound sonometer in a subset of 80 children (40/group)
|
At baseline, 3, 6, 9, 12 and 15 months of infant age
|
Additional growth parameters: weight
Time Frame: At infant age ≤14 days (baseline), 1, 2, 3, 4, 6, 9, 12 and 15 months of age
|
Weight in grams and corresponding weight-for-age Z-score according WHO growth standards
|
At infant age ≤14 days (baseline), 1, 2, 3, 4, 6, 9, 12 and 15 months of age
|
Additional growth parameters: length
Time Frame: At infant age ≤14 days (baseline), 1, 2, 3, 4, 6, 9, 12 and 15 months of age
|
Length in centimeters and corresponding length-for-age Z-score according WHO growth standards
|
At infant age ≤14 days (baseline), 1, 2, 3, 4, 6, 9, 12 and 15 months of age
|
Additional growth parameters:head circumference
Time Frame: At infant age ≤14 days (baseline), 1, 2, 3, 4, 6, 9, 12 and 15 months of age
|
Head circumference in centimeters and corresponding head circumference-for-age Z-score according WHO growth standards
|
At infant age ≤14 days (baseline), 1, 2, 3, 4, 6, 9, 12 and 15 months of age
|
Additional growth parameters: Body Mass Index
Time Frame: At infant age ≤14 days (baseline), 1, 2, 3, 4, 6, 9, 12 and 15 months of age
|
BMI (kg/m2) and corresponding BMI-for-age Z-score according WHO growth standards
|
At infant age ≤14 days (baseline), 1, 2, 3, 4, 6, 9, 12 and 15 months of age
|
Dietary pattern
Time Frame: At infant age 6, 9, 12 and 15 months
|
Data collected using a food frequency questionnaire including key food groups for infants and young children
|
At infant age 6, 9, 12 and 15 months
|
Absenteeism (infant and parent)
Time Frame: Data collected continuously from enrollment until 15 months of age
|
Time away from daycare (infant) or work (parent) will be recorded during occurrences of illness / infection using a calendar-based electronic Infant Illness Diary (IID)
|
Data collected continuously from enrollment until 15 months of age
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 20.12.INF
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Infants
-
Société des Produits Nestlé (SPN)Completed
-
CHU de ReimsCompleted
-
Danone Asia Pacific Holdings Pte, Ltd.CompletedHealthy InfantsThailand, Indonesia
-
Junlebao Dairy Group Co., Ltd.Merieux NutriSciences (China)Recruiting
-
NestléCompleted
-
Danone NutriciaNutricia Early Life Nutrition (Shanghai) Co., LtdCompletedHealthy InfantsChina
-
Monell Chemical Senses CenterEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
Seattle Children's HospitalCompleted
-
Heinz Italia SpAUniversity of Cagliari; IRCCS Policlinico S. MatteoCompletedFormula Feeding of Healthy Full Term Infants | Breast Feeding of Healthy Full Term InfantsItaly
-
Société des Produits Nestlé (SPN)Not yet recruitingHealthy Infants
Clinical Trials on Experimental formulas (EF)
-
Société des Produits Nestlé (SPN)RecruitingPre-term InfantPoland, Serbia, Slovakia
-
Everfront Biotech Co., Ltd.Not yet recruitingPancreatic Cancer
-
University of California, San DiegoRady Children's Hospital, San DiegoRecruitingOverweight and Obesity | Attention-Deficit Hyperactivity DisorderUnited States
-
Mahidol UniversityNational Research Council of ThailandCompletedDiabetes Mellitus, Type 2Thailand
-
Concordia University, MontrealCanadian Institutes of Health Research (CIHR)RecruitingAging | Age Related Hearing LossCanada
-
Second Affiliated Hospital, School of Medicine,...Recruitingthe Accuracy of Intraocular Lens Calculation FormulaChina
-
University Hospital, MontpellierRecruitingIschemic Stroke | Migraine | Migraine With AuraFrance
-
Stanford UniversityThe Clorox CompanyCompletedInflammation | Metabolic Syndrome | Microbiome | Immune FunctionUnited States